Table 4.
Potential Negative Practices and Suggested Beneficial Approaches for MHT in Postmenopausal CVD.
Potentially Negative | Potentially Beneficial |
---|---|
MHT using CEE | MHT using 17β-estradiol |
Oral administration of MHT | Transdermal administration of MHT |
Beginning of MHT late after menopause | Beginning of MHT early after menopause |
High dose of MHT | Low dose of MHT |
Progestins with adverse effects (MPA) | Cyclic administration of MHT Drospirenone Administration |